

PROVIDER QUICK POINTS

PROVIDER INFORMATION



August 12, 2020

MHCP Pharmacy Benefit Update – Pharmacy Benefit Exclusion for Anjeso™, Fetroja®, Herzuma®, Ontruzant®, Potassium Phosphates, Scenesse® and Trazimera™

The drugs listed in the table below shall be considered excluded from pharmacy benefit coverage effective July 3, 2020 due to clinician-administered route of administration and the availability for medical benefit coverage for subscribers who are eligible.

Drug Name and Strength
Anjeso™ (meloxicam injection) 30 mg/mL
Fetroja® (cefiderocol solution) 1 gm
Herzuma® (trastuzumab-Pkrb Solution) 150mg, 420mg
Ontruzant® (trastuzumab-Dttb Solution) 150mg, 420mg
Potassium Phosphates 45 Mm/15mL (Phos) 71 Meq/15ml (K) (potassium solution)
Scenesse® (afamelanotide implant) 16gm
Trazimera™ (trastuzumab-Qyyp Solution) 420mg

Products Impacted

This applies to the following Minnesota Health Care Programs.

- Families and Children [*formerly known as* Prepaid Medical Assistance Program (PMAP)]
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

Questions?

If you have questions for a member enrolled in a Minnesota Health Care Programs (MHCP) plan, please contact provider services at **1-866-518-8448**. Please contact provider services at **(651) 662-5200** or **1-800-262-0820** for all other questions.